Beverly Hills, CA -- (ReleaseWire) -- 10/22/2012 -- http://52WeekLowStock.com provides subscribers with a free newsletter that reports up to the minute information and exclusive charts on cheap, undervalued, hidden, and undiscovered stocks making new lows in the United States that can bounce.
The Dow and S&P 500 edged lower in choppy trading Monday, extending losses after major averages logged their worst one-day decline since June, following some mixed quarterly results that highlighted the impact of slower global growth on corporate revenues.
OXiGENE, Inc. is a clinical-stage, biopharmaceutical company developing therapeutics primarily to treat cancer. The Company’s primary focus is the development of product candidates referred to as vascular disrupting agents (VDAs), that disable and destroy abnormal blood vessels that provide solid tumors a means of growth and survival and also are associated with visual impairment in a number of ophthalmological diseases and conditions. ZYBRESTAT is its lead candidate. It is evaluating ZYBRESTAT in a randomized, controlled Phase II clinical trial, which it refer to as the FALCON trial, as a first-line treatment for stage IIIB/IV non-small cell lung cancer (NSCLC).The Company is pursuing development of OXi4503, a second-generation, dual-mechanism VDA, as a treatment for certain solid tumor types and for the treatment of myeloid leukemia’s. The stock hit a new low of $0.452 on Monday
DISCOVER STOCKS READY TO BOUNCE
52Weeklowstock.com is working on its next Undiscovered Company Special Report. These Special Reports typically see fast gains. Reports are issued to members only, Goto http://52weeklowstock.com to subscribe for free.
Disclosure: 52 Week Low Stock is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. This press release may contain several forward looking statements. Please read our report and visit our website for complete risks and disclosures.